2.77
+0.065(+2.41%)
Currency In USD
| Previous Close | 2.7 |
| Open | 2.79 |
| Day High | 2.82 |
| Day Low | 2.74 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.33 |
| Volume | 144,229 |
| Average Volume | 970,478 |
| Market Cap | 82.27M |
| PE | -3.04 |
| EPS | -0.91 |
| Moving Average 50 Days | 2.93 |
| Moving Average 200 Days | 2.07 |
| Change | 0.07 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $67.03 as of October 20, 2025 at a share price of $2.765. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $69.56 as of October 20, 2025 at a share price of $2.765.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
GlobeNewswire Inc.
Oct 01, 2025 12:05 PM GMT
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
GlobeNewswire Inc.
Oct 01, 2025 12:00 PM GMT
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a C
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:30 PM GMT
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equ